Author Affiliations1FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
2FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
3FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
4FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
5FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
6FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
7FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
8FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
9FSBI Hematology Research Center Minzdrava Russia 125167, Moscow, Novy Zykovsky av., 4
1. Allan N.C., Richards S.M., Sheperd P.C.A. et al. UK Medical Research Council randomized multicenter trial of interferon-alfa in chronic myeloid leukemia: improved survival irrespective of cytogenetic response // Lancet. 1995. 345. 1392–1397.
2. Baccarani M., Russo D., Rosti G., Martinelli G. Interferon-alfa for chronic myeloid leukemia // Semin. Hematol. 2003. 40. 22–33.
3. Baccarani M. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia-net // JCO. 2009. 27. (35). 6041–6051.
4. Baccarani M., Saglio G., Goldman J.M. et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-net // Blood. 2006. 108. 1809–1820.
5. Bonifazi F., De Vivo A., Rosti G. et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders // Blood. 2001. 98. 3074–3081.
6. Deenik W., van der Holt B., Verhoef G.E.G. et al. // Dose-finding study of imatinib in combination with intravenous cytarabine: Feasibility in newly diagnosed patients with chronic myeloid leukemia // Blood. 2008. 111. 2581–2588.
7. Guilhot F., Mahon F.X., Guilhot J. et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (CP): First results of the phase III (SPIRIT) trial from the French CML Group (Fl LMC) // Blood. 2008. 112. (74). 74.
8. Hasford J., Pfirrmann M., Hehlmann R. et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa // J. Natl. Cancer Inst. 1998. 90. 850–858.
9. Hehlmann R., Berger U., Pfirrmann M. et al. Randomized comparison of interferon a and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): prolongation of survival by the combination of interferon a and hydroxyurea // Leukemia. 2003. 17. 1529–1537.
10. Hehlmann R., Heimpel H., Hasford G., et al. Randomized comparison of interferon-alfa with busulfan and Hydroxyurea in chronic myelogenous leukemia // Blood. 1994. 84. (12). 4064–4077.
11. Palandri F., Lacobucci I., Castagnetti F., et al. Front-line treatment of Philadelphia-positive chronic myeloid leukemia with imatinib and interferon-alfa: 5-year outcome // 2008. 93. (5). 770–774.
12. Rousselot P., Huguet F., Rea D. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years // Blood. 2007. 109. (1). 58–60.
13. Sacchi S., Cortes J. et al. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia // Hematol. Mol. Hematol. 1997. 11. (1). 41–47.
14. Simonsson B. M., Gedde-Dahl M., Markevarn et al. Major molecular response rate at one year is higher if pegilated interferon alpha-2b is added to imatinib in non-HR CML leukemia patients in imatinib induced complete hematological remission // Blood. 2009. abstr 1110. 114. 3280.
15. Sokal J.E. Prognosis in chronic myeloid leukaemia: biology of the disease vs. Treatment // Baillieres Clin. Haematol. 1987. (1). 907–929.
16. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia// New Engl. J. Med. 1994. 330. 820–825.
About Authors (Correspondence):
Vinogradova O.Yu. – doctor of medical sciences, head of the group of medical registries of information and analytical service, е-mail: olgavinz@mail.ru
Turkina A.G. – doctor of medical sciences, professor, head of scientific and consultative department of myeloproliferative diseases chemotherapy, е-mail: turkianna@yandex.ru
Chelysheva E.Yu. – candidate of medical sciences, senior researcher of scientific and consultative department of myeloproliferative diseases chemotherapy, е-mail: denve@bk.ru
Gusarova G.A. – candidate of medical sciences, senior researcher of scientific and consultative department of myeloproliferative diseases chemotherapy, е-mail: galina1966@bk.ru
Kolosheinova T.I. – candidate of medical sciences, deputy head of scientific and clinical department of ambulatory assistance
Kolosova L.Yu. – candidate of medical sciences, physician of scientific and clinical department of ambulatory assistance, е-mail: Lkolosva@mail.ru
Goryacheva S.R. – candidate of medical sciences, physician of scientific and clinical department of ambulatory assistance
Vakhrusheva M.V. – candidate of medical sciences, physician of scientific and clinical department of ambulatory assistance
Khoroshko N.D. – doctor of medical sciences, professor, е-mail: khoroshko@blood.ru